<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
-------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 28, 2000
-------------
RIBOZYME PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Exact name of registrant as specified in charter)
Colorado 0-27914 34-1697351
------------------------ -------------------------- --------------------------
(State or other (Commission (IRS employer
jurisdiction of file number) identification no.)
incorporation
or organization)
2950 Wilderness Place, Boulder, Colorado 80301
--------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (303) 449-6500
--------------
N/A
--------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
<PAGE>
5. Other Events
On July 12, 2000, Ribozyme Pharmaceuticals, Inc. ("RPI"), announced results
regarding opposition proceedings against one of its ribozyme patents in Europe
(European Patent No. EP-B1 0291533). See Exhibit 99.1 attached hereto.
On July 18, 2000, RPI announced two promotions in its Research and
Development organization. See Exhibit 99.2 attached hereto.
On July 20, 2000 RPI announced additional information regarding European
Patent No. EP-B1 0291533. See Exhibit 99.3 attached hereto.
On July 21, 2000, RPI announced the receipt of a $1 million milestone
payment from partner Eli Lilly and Company. See Exhibit 99.4 attached hereto.
EXHIBITS
99.1 Press release dated July 12, 2000.
99.2 Press release dated July 18, 2000.
99.3 Press release dated July 20, 2000.
99.4 Press release dated July 21, 2000.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
RIBOZYME PHARMACEUTICALS, INC.
DATE: July 28, 2000 By: /s/ Lawrence E. Bullock
----------------------------------------------
Lawrence E. Bullock, Vice President of
Administration and Finance, Chief Financial
Officer and Secretary
-2-
